Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutathione, NAC, and ALA for Long COVID
NCT05371288Phase 1Withdrawn
- Sponsor
- University of California, Irvine
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glutathione in post acute COVID-19 syndrome (2 arms), sponsored by University of California, Irvine. Primary endpoints: Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC) at 4 months, Change in Quality of Life Using SF-36 Survey at 4 months and 2 more. Planned start Jun 2025; status: withdrawn.
02
Drugs
glutathione
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05371288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371288.